dapsone has been researched along with Carcinoma, Basal Cell, Pigmented in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dapsone 50 mg/day was administered, and the lesions gradually improved within some weeks, and no new lesions appeared." | 1.51 | Topical imiquimod-induced linear IgA bullous dermatosis. ( Alaibac, M; Ferranti, M; Tadiotto Cicogna, G; Vaccari, D, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tadiotto Cicogna, G | 1 |
| Ferranti, M | 1 |
| Vaccari, D | 1 |
| Alaibac, M | 1 |
| Ena, P | 1 |
| Lissia, M | 1 |
| Doneddu, GM | 1 |
| Campus, GV | 1 |
1 review available for dapsone and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Erosive pustular dermatosis of the scalp in skin grafts: report of three cases.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Infective Agents; | 1997 |
1 other study available for dapsone and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Topical imiquimod-induced linear IgA bullous dermatosis.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Carcinoma, Basal Cell; Dapsone; Facial Neopl | 2019 |